Food and Drug Administration

Cardiovascular and Renal Drugs Advisory Committee

July 18, 2002

Slides

Disclaimer

The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

Atacand Introduction and Regulatory Overview, Cindy Lancaster, MS, MBA, JD, AstraZeneca  htm  ppt

Comparison of the Antihypertensive Efficacy of Candesartan Cilexetil and Losartan, Dr. Vasilios Papademetriou, MD, DSc, FACC, Georgetown U. & VA Medical Ctr.  htm  ppt

Epidemiologic and Clinical Significance of Incremental Changes in Blood Pressure, Dr. William Kannel, MD, FACC, Boston U.  htm ppt

Atacand Summary, Cindy Lancaster, MS, MBA, JD, AstraZeneca  htm  ppt

Supportive Information, AstraZeneca   htm  ppt

Pravastatin-Aspirin Introduction, Dr. Todd Baumgartner, MD MPH, BristolMyers Squibb  htm  ppt

Pravastatin-Aspirin Safety and Dosing Considerations, Dr. Rene Belder, MD, Bristol-Myers Squibb  htm  ppt

Rationale and Context: Pravastatin-Aspirin Overview, Dr. Fred Fiedorek, MD, Bristol-Myers Squibb  htm  ppt

Supportive Information, Bristol-Myers Squibb  htm  ppt